{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-21-000916","form_type":"8-K","ticker":"RVTY","cik":"0000031791","company_name":"REVVITY, INC.","filed_at":"2021-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.325508+00:00","generated_at":"2026-06-30T02:45:14.468117+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PerkinElmer Q2 revenue $1.228B (+51%); raises guidance; to acquire BioLegend","bullets":["Revenue $1.228B, +51% reported, +41% organic; GAAP EPS $2.19, adjusted EPS $2.83.","Raises full-year revenue and earnings guidance; initiates Q3 guidance.","Agrees to acquire BioLegend, a leading antibody & research reagent provider.","GAAP operating margin 27.1% (vs 21.6% Q2 2020); adjusted margin 33.5% (vs 28.1%).","Earnings call moved to July 26 at 8:00 a.m. ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-21-000916","json":"https://secwatch.observer/filing/0001157523-21-000916.json","markdown":"https://secwatch.observer/filing/0001157523-21-000916.md","text":"https://secwatch.observer/filing/0001157523-21-000916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/31791/000115752321000916/0001157523-21-000916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/31791/000115752321000916/a52464567.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T02:45:14.468117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}